Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 70.14 Million USD | -49.39% |
| 2022 | 138.59 Million USD | 32.3% |
| 2021 | 104.75 Million USD | 51.69% |
| 2020 | 69.05 Million USD | 0.87% |
| 2019 | 68.45 Million USD | 12.98% |
| 2018 | 60.59 Million USD | 21.13% |
| 2017 | 50.02 Million USD | 2.43% |
| 2016 | 48.83 Million USD | 16.82% |
| 2015 | 41.8 Million USD | 18.4% |
| 2014 | 35.3 Million USD | 10.6% |
| 2013 | 31.92 Million USD | -63.85% |
| 2012 | 88.29 Million USD | -28.71% |
| 2011 | 123.86 Million USD | 15.65% |
| 2010 | 107.1 Million USD | 29.18% |
| 2009 | 82.9 Million USD | 64.25% |
| 2008 | 50.47 Million USD | 99.26% |
| 2007 | 25.33 Million USD | 108.9% |
| 2006 | 12.12 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 7.97 Million USD | -53.27% |
| 2024 Q3 | 12.83 Million USD | 60.83% |
| 2024 Q1 | 17.07 Million USD | -35.72% |
| 2023 FY | 70.14 Million USD | -49.39% |
| 2023 Q4 | 26.56 Million USD | 186.31% |
| 2023 Q2 | 21.32 Million USD | 64.25% |
| 2023 Q3 | 9.27 Million USD | -56.49% |
| 2023 Q1 | 12.98 Million USD | -57.26% |
| 2022 Q4 | 30.37 Million USD | -11.88% |
| 2022 Q3 | 34.47 Million USD | -10.25% |
| 2022 Q1 | 35.34 Million USD | 44.24% |
| 2022 Q2 | 38.4 Million USD | 8.68% |
| 2022 FY | 138.59 Million USD | 32.3% |
| 2021 Q3 | 36.76 Million USD | 44.46% |
| 2021 Q1 | 18.03 Million USD | -14.27% |
| 2021 Q4 | 24.5 Million USD | -33.37% |
| 2021 FY | 104.75 Million USD | 51.69% |
| 2021 Q2 | 25.45 Million USD | 41.15% |
| 2020 Q4 | 21.03 Million USD | 14.41% |
| 2020 FY | 69.05 Million USD | 0.87% |
| 2020 Q2 | 14.96 Million USD | 2.02% |
| 2020 Q1 | 14.67 Million USD | -21.34% |
| 2020 Q3 | 18.38 Million USD | 22.84% |
| 2019 Q2 | 12.31 Million USD | -20.95% |
| 2019 Q3 | 21.9 Million USD | 77.82% |
| 2019 FY | 68.45 Million USD | 12.98% |
| 2019 Q1 | 15.58 Million USD | -3.02% |
| 2019 Q4 | 18.65 Million USD | -14.86% |
| 2018 Q1 | 14.04 Million USD | -35.36% |
| 2018 Q4 | 16.06 Million USD | -5.18% |
| 2018 FY | 60.59 Million USD | 21.13% |
| 2018 Q3 | 16.94 Million USD | 25.17% |
| 2018 Q2 | 13.53 Million USD | -3.59% |
| 2017 Q1 | 7.97 Million USD | -20.04% |
| 2017 Q3 | 9.98 Million USD | -3.51% |
| 2017 Q2 | 10.34 Million USD | 29.81% |
| 2017 FY | 50.02 Million USD | 2.43% |
| 2017 Q4 | 21.72 Million USD | 117.57% |
| 2016 Q3 | 14.87 Million USD | -7.07% |
| 2016 FY | 48.83 Million USD | 16.82% |
| 2016 Q4 | 9.96 Million USD | -32.96% |
| 2016 Q2 | 16 Million USD | 100.13% |
| 2016 Q1 | 7.99 Million USD | -30.99% |
| 2015 FY | 41.8 Million USD | 18.4% |
| 2015 Q2 | 6.01 Million USD | -11.47% |
| 2015 Q1 | 6.79 Million USD | -52.1% |
| 2015 Q3 | 17.4 Million USD | 189.15% |
| 2015 Q4 | 11.58 Million USD | -33.41% |
| 2014 Q1 | 7.07 Million USD | -25.73% |
| 2014 Q2 | 6.57 Million USD | -7.12% |
| 2014 Q3 | 7.47 Million USD | 13.73% |
| 2014 Q4 | 14.19 Million USD | 89.92% |
| 2014 FY | 35.3 Million USD | 10.6% |
| 2013 Q1 | 11.48 Million USD | 45.11% |
| 2013 Q2 | 6.97 Million USD | -39.26% |
| 2013 Q3 | 3.94 Million USD | -43.46% |
| 2013 Q4 | 9.52 Million USD | 141.57% |
| 2013 FY | 31.92 Million USD | -63.85% |
| 2012 Q4 | 7.91 Million USD | -69.96% |
| 2012 FY | 88.29 Million USD | -28.71% |
| 2012 Q1 | 31.13 Million USD | -7.04% |
| 2012 Q3 | 26.34 Million USD | 14.98% |
| 2012 Q2 | 22.9 Million USD | -26.42% |
| 2011 Q1 | 31.03 Million USD | 4.1% |
| 2011 Q2 | 26.05 Million USD | -16.04% |
| 2011 Q3 | 33.28 Million USD | 27.74% |
| 2011 Q4 | 33.49 Million USD | 0.63% |
| 2011 FY | 123.86 Million USD | 15.65% |
| 2010 Q3 | 27.11 Million USD | 10.76% |
| 2010 Q1 | 25.7 Million USD | 6.03% |
| 2010 Q4 | 29.81 Million USD | 9.95% |
| 2010 FY | 107.1 Million USD | 29.18% |
| 2010 Q2 | 24.48 Million USD | -4.75% |
| 2009 FY | 82.9 Million USD | 64.25% |
| 2009 Q1 | 19.41 Million USD | 4.37% |
| 2009 Q4 | 24.23 Million USD | 20.82% |
| 2009 Q3 | 20.06 Million USD | 4.5% |
| 2009 Q2 | 19.19 Million USD | -1.09% |
| 2008 Q4 | 18.59 Million USD | 0.0% |
| 2008 FY | 50.47 Million USD | 99.26% |
| 2008 Q1 | 8.37 Million USD | 0.0% |
| 2007 Q1 | 4.7 Million USD | 0.0% |
| 2007 FY | 25.33 Million USD | 108.9% |
| 2006 FY | 12.12 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 57.207% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 70.863% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -22238.535% |
| Organovo Holdings, Inc. | 109 Thousand USD | -64251.376% |